Every patient will receive a 120 second treatment cycle, however, the amount of energy delivered during the 120 seconds will vary from patient to patient depending on uterine cavity size and thickness of the endometrium. Each ablation starts with a maximum of 40W of power and declines over the course of the ablation as the impedance within the cavity increases.
The Minerva EAS does not rely solely on direct tissue contact to achieve optimal ablation. Three simultaneous and complementary methods of tissue ablation are being employed by the Minerva EAS, providing a truly global ablation.
The Minerva EAS is the only ablation system that modulates the power level over the course of the ablation cycle. The controller adjusts power in real time by assessing the changes in the state of the uterine cavity during the ablation process, with measurements being taken and adjustments made 50 times per second. During the ablation process, the area of unablated tissue decreases, and power starts dropping accordingly, with plasma being redirected.
Thus focusing ONLY on the least ablated endometrium for a uniform surface area coverage and depth of ablation.
Plasma is another term for ionized gas, in this case argon. The argon gas inside the membrane is ionized by the RF energy delivered to the handpiece from the Minerva Controller.
The cervix should be dilated. An 8mm Hegar dilator is included in the device packaging. The dilator has graduated length markings to ensure accurate measurement of the cervix.
Do not turn off the Controller. Most error codes may be resolved via troubleshooting or replacing the handpiece. Then the Controller will proceed through the safety checks and resume and ablate for the remaining treatment time. In rare instances, a hard fault may be encountered that would require cycling off power to the Controller. Consult the Operator’s Manual or call Axora Medical at 855-646-7874 for more information.
The cervical sealing balloon can be inflated a maximum of 2 times. If a cervical seal still cannot be achieved, reassess to make sure the device is properly positioned in the uterine cavity and rule out uterine perforation.
In a clinical study, patients who underwent treatment with the Minerva EAS achieved an amenorrhea rate of 72%, or 7 out of 10 women, at 1-year followup1.
1. Laberge P, Garza-Leal J, Fortin C, Grainger D, Johns DA, Adkins RT, Presthus J, Basinski C, Swarup M, Gimpelson R, Leyland N, Thiel J, Harris M, Burnett PE, Ray GF. A Randomized Controlled Multicenter US Food and Drug Administration Trial of the Safety and Efficacy of the Minerva Endometrial Ablation System: One-Year Follow-Up Results. J Minim Invasive Gynecol. 2017 Jan 1;24(1):124-132. doi: 10.1016/j.jmig.2016.09.009. Epub 2016 Sep 26. PMID: 27687851.
At three years following the procedure, the Minerva EAS treated patients had a 0.9% hysterectomy rate.2 While studies from different clinical investigations are not comparable, for educational purposes only, in their own separate clinical study NovaSure reported a 6.3% hysterectomy rate at 3 years in its IFU.3
2. Data on file, Minerva Single Arm Clinical Study, Minerva Endometrial Ablation System Instructions for Use, L0107 Rev. F. Axora Medical.
3. NovaSure V5 Device Instructions for Use, Revision 003. Hologic, https://www.hologic.com/package-inserts/gyn-surgical-products/novasure-endometrial-ablation?_gl=1*fjxi2n*_gcl_au*OTk2MDE5OTE2LjE3MzgxODgwODA. Accessed 17 Mar. 2026.
The argon Canister will last for approximately 7 treatments. A CO2 Canister will last for approximately 25 treatments.
No. According to the product labeling, use of the Minerva EAS, and all other second-generation endometrial ablation technologies, is contraindicated in a patient with any anatomic condition that could lead to weakening of the myometrium. Please consult instructions for use for complete indications, contraindications, warnings and precautions.
The Minerva treatment should not be performed concomitantly with the placement of the Essure device. The safety and effectiveness of the Minerva treatment has not been evaluated in patients with the Essure device.
Yes. Symphion® is indicated for resection of any intrauterine tissue. By design, there is only one Resecting Device size, which is independent of the type and size of pathology for a more streamlined, cost effective, and minimally invasive solution for treatment of AUB due to structural causes.
No, the Symphion system does not use a mechanical blade. It uses bipolar radiofrequency (RF) plasma to resect and coagulate tissue, eliminating the need for a mechanical blade that may dull over time.
Symphion is designed to volumetrically limit the amount of distention media that potentially can be absorbed, and this value will never exceed 2500mL. This is achieved via Symphion’s “closed loop” fluid management system. The re-circulating distention media allows the user to calculate the fluid loss by simply subtracting the remainder of fluid in the 3000mL saline bag from the operating volume of 2500mL. However, an optional fluid deficit readout accessory is available for use with the Symphion Prime controller.
Total Fluid Loss equals 2500mL minus amount of saline remaining in the 3000mL bag (approximately 500mL remains in the system).
No. Symphion uses bladeless RF plasma resection technology. As a result, the Resecting Device does not dull or weaken during treatment.
Symphion has an independent aspiration mode.
Histologic evaluation of the tissue chips indicates a consistent depth of tissue thermal effect limited to ~80 microns.
No. The Symphion Fluid Management Accessory (FMA) is all-inclusive.
A 3.0mm diameter or smaller diagnostic hysteroscope can be used with the corresponding adapter.
Yes. To order, contact Axora Medical Customer Service at 855-646-7874.
Genesys HTA operates between 50-60mmHg of pressure.
Target temperature is 90 degrees Celsius and will fluctuate several degrees during the treatment cycle.
Yes. Only use normal saline (0.9%).
No. You can use a single scope in conjunction with the Genesys HTA setup. No additional or separate setups are required.
Resectr comes in one size:
5Fr outer diameter, 5mm cutting window, 35cm length
The 5Fr Resectr may be used with any hysteroscope that has an operative channel of 5Fr or larger.
No. Resectr is a handheld device that is powered by squeezing the handle of the device. No external power source is needed. A source of suction (wall or pump) is required.
The Resectr is labeled for resection of any intrauterine pathology/tissue, but is especially effective with endometrial polyps.
An operative hysteroscope, a source of suction, a source of distention media, tubing for inflow and outflow, and a tissue catch for pathology. To order the Resectr accessories, please go to www.precisionmedical.com/Minerva.
The Resectr utilizes purely mechanical cutting.
Yes. The rotating collar that enables window rotation is located on the connection of the cannula to the handle. This allows for easy and ergonomic case execution, reducing procedure time and physician fatigue.
The HERizon Vista System is intended to be used for viewing of the adult cervical canal and uterine cavity for the purpose of performing diagnostic and operative procedures, such as biopsy or targeted tissue removal when used with compatible accessories.
The HERizon Vista System is designed for use across multiple care settings, including physician offices, surgery centers, and hospital ORs.
No. The HERizon Vista single-use hysteroscopes must be connected to the HERizon Vista ViewPoint Endoscopic Video Image Processor.
A source of suction, a source of distention media, tubing for inflow and outflow, and a tissue catch for pathology. Ask your Axora Medical representative about our HERizon Hysto-Kit, which includes supplies for performing a hysteroscopic exam.
Single-use hysteroscopes eliminate the need for reprocessing between procedures.
No. The HERizon Vista Single-Use Hysteroscopes are for single use only. Reusing, reprocessing, or resterilization may compromise the structural integrity of the device and/or lead to device failure which, in turn, may result in patient injury, illness or death.
Reusing, reprocessing or resterilization may also create a risk of contamination of the device and/or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device may result in patient injury, illness or death.
After use, dispose of product and packaging in accordance with hospital, administrative and/or local government policy.
The HERizon Vista System can be used in conjunction with a variety of optional accessories. The HERizon Vista Single-Use Hysteroscope, Model 2 working channel has an inner diameter of 6 Fr. Additional accessories may be used which are compatible with this size of a working channel, such as:
